Funding for this research was provided by:
Pierre Fabre Pharma Italy
Text and Data Mining valid from 2020-02-14
Received: 10 December 2019
Accepted: 23 January 2020
First Online: 14 February 2020
Compliance with ethical standards
: C De Nunzio: consultant for Pierre-Fabre, Janssen and Astellas. V Ficarra: honoraria for speaking at symposia from Pierre Fabre and research grants from IDIPharma. M Gacci: company consultant, trial participation, fellowship, travel grant, receipt of grants/research supports for Astellas, Bayer, GSK, Ibsa, Konpharma, Lilly, Menarini, Pierre Fabre and Recordati. A Salonia: no conflict of interest.